Eli Lilly Fully Exits RIPK1 Inhibitor Collaboration with Rigel, Citing Failure to Meet Development Standards

In recent years,The RIPK1 project is not going well, leading to more and more pharmaceutical giants stepping back fromRIPK1 Retreats in Development.

The latest to announce abandonment is Eli Lilly. The reason is that the candidate drug failed to meet Eli Lilly's high standards.

Lilly TerminatesRIPK1 Collaboration

Recently, according to an SEC filing, Eli Lilly has fully terminated its collaboration with Rigel Pharmaceuticals on the RIPK1 inhibitor project. The termination will take effect on June 15, 2026.

Eli LillyThe collaboration with Rigel began on February 18, 2021, when both parties signed a licensing and collaboration agreement. According to the terms of the collaboration,Lilly will pay $125 million upfront and has committed to milestone payments of up to $835 million,Rigel willGranting Lilly aboutOcadusertib (formerly known asR552) for non-central nervous system (CNS) diseases, and other RIPK1 inhibitor projects forCNS DiseasesExclusive rights for development, production, and commercialization worldwide.

And in November 2025,Eli Lilly and CompanyHas terminated the R&D portion of the collaboration targeting central nervous system (CNS) diseases.

Until now,Lilly has completely terminated its partnership withRigel AboutCollaboration on the RIPK1 inhibitor project. According to the termination agreement,Rigel will regain at the termination of the agreementOcadusertib andRights related to RIPK1 inhibitors.

The reason for Lilly's decision to terminate the collaboration,According to a statement,A spokesperson for Eli Lilly said: "Ocadusertib failed to meet our high standards for continued development.”

The Retreat Trend of RIPK1

RIPK1 is a key cellular kinase,It is an important mediator of inflammation and death signaling, and an effective target for the treatment of various diseases such as neurodegenerative diseases, autoimmune diseases, and inflammation.At the same timeRIPK1InTumor cells also play an important role in evading the immune system.

Therefore,RIPK1 is considered a promising targeted therapeutic option. HoweverThe development of RIPK1 has not been smooth in recent years.As for an increasing number of pharmaceutical giants are moving fromRIPK1 Withdrawn from Development.

First is GSK, GSK can be said to bePioneer in the development of RIPK1 inhibitors.

GSK as early as 2014RIPK1 InhibitorGSK2982772Advanced to the clinical stage, but its development was not smooth — it failed to meet the primary efficacy endpoint in multiple clinical studies, leading to GSK abandoning this pipeline.

In 2019, GSK also terminated the development of another RIPK1 drug, GSK095, for the treatment of pancreatic cancer, in combination with K药 (Keytruda).

In 2021, GSK licensed the RIPK1 drug GSK3502421 to Boston Pharmaceuticals.

In public materials, GSK did not disclose anyRIPK1-related R&D plans or clinical trials indicate that GSK has largely withdrawn from direct research on this target.

Sanofi is also giving upDevelopment of RIPK1 Inhibitors.

Sanofi partnered with Denali Therapeutics in 2018 to developRIPK1 inhibitor. According to Sanofi's 2025 financial report, it has terminated the last RIPK1 inhibitor project in collaboration with Denali and downgraded its priority.

In fact, in Sanofi andSeveral in the Denali collaborationRIPK1All candidate drugs have failed. The first candidateRIPK1 Inhibitors Due toPreclinical chronic toxicity study results were unsatisfactory, leading to its abandonment; the second candidateRIPK1 InhibitorOditrasertib was abandoned because it failed to meet the primary endpoints in Phase II clinical trials for both amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); the third candidateRIPK1 InhibitorEclitasertib has also been deprioritized due to unsatisfactory clinical development.

Roche/Genentech TerminationRIPK1 inhibitor.

In March 2026, Genentech, a subsidiary of Roche, made the decision,Early termination of the Phase II trial for its RIPK1 inhibitor flizasertib (GDC-8264) due to interim data indicating the drug is unlikely to demonstrate significant clinical benefit in preventing acute kidney injury after cardiac surgery; this asset has also been removed from the development pipeline.

In addition, Eli Lilly has decided to fully terminate its collaboration with Rigel on the RIPK1 inhibitor project.

Four giants have already exited.Research on RIPK1 inhibitors.

Summary

DespiteThe development of RIPK1 inhibitors has not been smooth, and the withdrawal of several giants has affected the industry'sEvaluation of RIPK1 Inhibitors.

But based onThe Unique Physiological Role and Potential Therapeutic Value of RIPK1There are still quite a few companies persisting in development.RIPK1。

References:

1.https://www.fiercebiotech.com/biotech/lilly-reneges-remainder-rigel-deal-another-blow-ripk1-inhibitors

2.https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000027/0001034842-26-000027.pdf